According to media sources, the weight loss drug, Orexigen, has been rejected by the Food and Drug Administration. FDA announced today that they have conducted a detailed study on the effects of Contrave on the heart.
The authorities have said that Contrave, which is a mixture of the antidepressant bupropion and the anti addiction drug naltrexone, works by boosting metabolism while curbing appetite and cravings.
The weight loss drug, Orexigen Therapeutics’ Contrave, got a 13 to 7 majority voting approval in December and it was endorsed by an FDA advisory committee. The agency later became concerned about Orexigen Therapeutics’ Contrave’s safety.
According to the administration, the pilot clinical testing they conducted for Orexigen Therapeutics’ Contrave consisted of 5000 participants out of which nearly 35% lost at least 5% of their body weight; however, they also experienced a slight increase in their blood pressures.